Carna Biosciences, Inc. Reports Consolidated Financial Results for the Nine Months Ended Sep. 30, 2017; Provides Financial Guidance for the Year Ending Dec. 31, 2017
Carna Biosciences, Inc. reported consolidated financial results for the nine months ended Sep. 30, 2017. For the nine months, the company reported operating loss of ¥477 million and loss attributable to owners of parent of ¥508 million or ¥54.46 per basic share on net sales of ¥483 million against operating loss of ¥334 million and loss attributable to owners of parent of ¥178 million or ¥19.52 per basic share on net sales of ¥581 million for the same period of last year. Loss before income taxes was ¥505.4 million against ¥176.6 million for the same period of last year.
For the year ending Dec. 31, 2017, the company expects, operating loss of ¥727 million and loss attributable to owners of parent of ¥766 million or ¥82.12 per basic share on net sales of ¥701 million.